Istradefylline (KW-6002)
Istradefylline (KW-6002) is a pharmaceutical drug with 9 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 9 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
5
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
9 of 9 finished
0.0%
0 ended early
0
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
Clinical Trials (9)
A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9